Elicio Therapeutics, Inc.
(Note: Elicio Therapeutics, Inc. withdrew its IPO plans in an SEC filing dated Sept. 13, 2022. The IPO was postponed in late July 2021. Elicio Therapeutics filed its S-1 in June 2021.)
We are a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. For therapies designed to engage the immune system to treat disease, it is critical to target activation at the unique location where adaptive immune responses are generated. Our proprietary Amphiphile, or AMP, platform delivers immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. We believe this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators will more efficiently educate, activate, and amplify critical immune cells, resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, we have observed lymph-node specific engagement driving therapeutic immune responses of increased magnitude, function and durability. We believe our AMP lymph node targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes.
Our lead product candidate, ELI-002, is being developed to treat cancers driven by KRAS, a mutation found in approximately 25% of tumors. We are conducting a Phase 1/2 clinical trial of ELI-002 (AMPLIFY-201) and anticipate initial safety, dose escalation, and correlative biomarker data in the first half of 2022.
We are also evaluating the potential use of ELI-004, our universal AMP-modified CpG adjuvant, and a component of ELI-002, in conjunction with other disease-specific antigens, to treat or prevent additional diseases.
(Note: Elicio Therapeutics postponed its IPO on July 28, 2021.)
|Address||One Kendall Square, Suite 14303, Cambridge, MA 02139|
|Phone Number||(857) 209-0050.|
|View Prospectus:||Elicio Therapeutics, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-18.9 mil (last 12 months)|
|Price range||$12.00 - $14.00|
|Est. $ Volume||$40.0 mil|
|Manager / Joint Managers||BTIG/ Oppenheimer & Co.|
|Expected To Trade:||7/26/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|